Century Therapeutics stock falls 6.88 percent as milestones approach

Century Therapeutics stock fell 6.88 percent to USD 1.76 on Nasdaq on September 23, 2026, leaving the biotechnology company 42.1 percent below its 52-week high of USD 3.04. The move came as investors weighed a quarterly loss against upcoming clinical milestones.

Quarterly loss misses consensus

Century Therapeutics reported adjusted earnings per share of USD -0.17 for the second quarter of 2026, compared with the USD -0.11 consensus estimate, a USD 0.06 shortfall, according to MarketBeat. The result keeps operating spending and cash use central to the investment case for a clinical-stage company.

The stock's market capitalization stood at USD 152,362,125 on September 23, 2026, while trading volume reached 508,081 shares. Its 52-week range was USD 0.43 to USD 3.04, placing the latest price USD 1.33 below the yearly high.

Pipeline milestones set the next test

On September 9, 2026, Century Therapeutics said CNTY-813 remained on track for an investigational new drug submission in the fourth quarter of 2026. The company said a pre-IND meeting with the FDA produced alignment on the nonclinical data package, manufacturing strategy, and proposed Phase 1/2 trial design.

CNTY-813 is an iPSC-derived islet replacement therapy for type 1 diabetes, while Century also develops cell therapies for cancer. That creates a clear split in the stock narrative: the USD 0.06 quarterly EPS miss weighs on near-term sentiment, while the fourth-quarter regulatory milestone offers a measurable test of execution.

Stock stays below yearly high

Century Therapeutics stock stood at USD 1.76 on Nasdaq on September 23, 2026, with a daily change of -6.88 percent. The price was 42.1 percent below the 52-week high of USD 3.04, making the upcoming CNTY-813 filing milestone the next company-specific checkpoint.